Department of Surgical Sciences, Section of Vascular Surgery, Uppsala University, Uppsala, Sweden.
Department of Surgical Sciences, Section of Vascular Surgery, Uppsala University, Uppsala, Sweden.
Eur J Vasc Endovasc Surg. 2019 Sep;58(3):426-435. doi: 10.1016/j.ejvs.2019.05.004. Epub 2019 Jul 16.
The aim of this systematic literature review was to compile an updated overview of mycotic aortic aneurysm (MAA) treatment and outcomes.
A systematic literature review was performed using the search terms mycotic and infected aortic aneurysms in the MEDLINE and ScienceDirect databases, published between January 2000 and September 2018. Using the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, articles were scrutinised regarding surgical technique, aortic segment involved, pre- and post-operative antibiotic regimens, survival and infection related complications (IRCs), and factors associated with adverse or favourable outcomes.
Twenty-eight studies, with a total of 963 patients, were included. All publications were observational, retrospective studies. Patient and study heterogeneity, along with missing data, precluded meta-analyses. Overall treatment consisted of open surgical repair (OSR; n = 556 [58%]), endovascular aortic repair (EVAR; n = 373 [39%]), and medical treatment alone (n = 34 [3%]). OSR was the dominant surgical technique prior to 2010, shifting to EVAR thereafter. For MAAs located in the abdominal aorta, EVAR was associated with better short term survival than OSR. Antibiotic treatment for more than six months post-operatively was associated with better survival, but there was no consensus on the length of treatment. MAAs were complicated by IRCs in 21%, irrespective of surgical technique, of which 46%-70% were fatal. The most consistently reported factors associated with adverse outcomes were increasing age, rupture, suprarenal abdominal aneurysm location, and non-Salmonella positive culture.
With few exceptions, the literature mainly consists of small, retrospective single centre studies. Standardised reporting is needed to increase comparability of studies. EVAR appears to be associated with superior short term survival without late disadvantages, compared with OSR. This suggests that EVAR can be an acceptable alternative to OSR. However, MAA treatment should always be tailor made and planned individually, and general recommendations are in vain. IRCs pose a significant threat to patients after MAA repair and require further investigation.
本系统文献回顾的目的是对真菌性腹主动脉瘤(MAA)的治疗和结果进行最新综述。
使用 MEDLINE 和 ScienceDirect 数据库中的搜索词“真菌性”和“感染性主动脉瘤”进行系统文献回顾,检索时间为 2000 年 1 月至 2018 年 9 月。根据系统评价和荟萃分析的首选报告项目(PRISMA)声明,仔细检查了手术技术、涉及的主动脉节段、术前和术后抗生素方案、存活率和感染相关并发症(IRC)以及与不良或有利结果相关的因素。
纳入 28 项研究,共 963 例患者。所有出版物均为观察性、回顾性研究。患者和研究的异质性以及数据缺失使得无法进行荟萃分析。总体治疗包括开放性手术修复(OSR;n=556 [58%])、血管内修复(EVAR;n=373 [39%])和单独药物治疗(n=34 [3%])。OSR 是 2010 年前主要的手术技术,此后 EVAR 成为主流。对于位于腹主动脉的 MAA,EVAR 与短期生存率优于 OSR。术后 6 个月以上的抗生素治疗与生存率提高相关,但治疗时间长短没有共识。IRC 并发症在 21%的患者中发生,无论手术技术如何,其中 46%-70%是致命的。报告最一致的与不良结果相关的因素是年龄增长、破裂、肾上腹主动脉瘤位置和非沙门氏菌阳性培养。
除了少数例外,文献主要由小的、回顾性的单中心研究组成。需要标准化报告以提高研究的可比性。与 OSR 相比,EVAR 似乎与短期生存率的提高相关,而无晚期劣势。这表明 EVAR 可以作为 OSR 的一种可接受的替代方法。然而,MAA 治疗应始终根据个体情况进行定制和计划,一般建议是无效的。IRC 对 MAA 修复后的患者构成重大威胁,需要进一步研究。